| Name | Title | Contact Details |
|---|---|---|
Spencer Clark |
SVP and General Counsel | Profile |
Roxanne Womack |
SVP, Chief Compliance Officer | Profile |
Spencer Clark |
VP and Senior Legal Counsel | Profile |
Kelly Whelan |
VP and Senior Legal Counsel, American and Eastern Groups | Profile |
Bayer MaterialScience is the global market leader in polyurethanes. The company develops and produces the components for rigid and flexible foams as well as for solid materials. Diverse applications range from mattresses and ski boots to insulating materials for refrigeration appliances and buildings. Bayer MaterialScience is also the leader in the development and production of polycarbonates. Lightweight, tough and freely formable, these high-performance plastics can be used in a wide variety of applications, including in the automotive and construction industries. Bayer MaterialScience is also one of the world’s leading suppliers of raw materials for coatings, adhesives and sealants. These products protect and enhance the appearance of such things as automobiles and furniture, and are used in the sports and leisure sector. In addition, Bayer MaterialScience supplies the chemical industry with numerous basic chemicals.
LaBelle Strategic Resources is a Collegeville, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Grand Valley Technology Services is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.
Centerstone is a not-for-profit health system providing mental health and substance use disorder treatments. Services are available nationally through the operation of outpatient clinics, residential programs, the use of telehealth and an inpatient hospital. Centerstone also features specialized programs for the military community, therapeutic foster care, children`s services and employee assistance programs. Centerstone`s Research Institute provides guidance through research and technology, leveraging the best practices for use in all our communities. Centerstone`s Foundation secures philanthropic resources to support the work and mission of delivering care that changes people`s lives.